Literature DB >> 3423903

Capgras delusion and seizures in association with therapeutic dosages of disulfiram.

D G Daniel1, A Swallows, F Wolff.   

Abstract

We have described a patient in whom EEG abnormalities, a seizure disorder, and Capgras syndrome developed two weeks after she started taking disulfiram. That disulfiram has been shown to inhibit dopamine beta-hydroxylase in vitro suggests an etiologic role for dopaminergic pathways in at least some cases of Capgras syndrome. Our experience with this patient suggests that convulsions and psychosis may occur as a side effect of standard dosages of disulfiram in patients with no previous history of psychosis or brain disease. Furthermore, the symptoms may resolve spontaneously without the long-term use of antipsychotic or anticonvulsant medication.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3423903     DOI: 10.1097/00007611-198712000-00022

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

1.  Responses to facial and non-facial stimuli presented tachistoscopically in either or both visual fields by patients with the Capgras delusion and paranoid schizophrenics.

Authors:  H D Ellis; K W de Pauw; G N Christodoulou; L Papageorgiou; A B Milne; A B Joseph
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

2.  Delusional misidentification of health care professionals.

Authors:  J A Silva; G B Leong; M M Ferrari
Journal:  Psychiatr Q       Date:  1995

3.  Capgras' syndrome in first-episode psychotic disorders.

Authors:  Paola Salvatore; Chaya Bhuvaneswar; Mauricio Tohen; Hari-Mandir K Khalsa; Carlo Maggini; Ross J Baldessarini
Journal:  Psychopathology       Date:  2014-02-07       Impact factor: 1.944

4.  Effects of disulfiram and dopamine beta-hydroxylase knockout on cocaine-induced seizures.

Authors:  Meriem Gaval-Cruz; Jason P Schroeder; L Cameron Liles; Martin A Javors; David Weinshenker
Journal:  Pharmacol Biochem Behav       Date:  2008-02-12       Impact factor: 3.533

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.